EVE eve health group limited.

0.00%

3.5¢

Sorta makes me laugh "the safety and efficacy data" Where was...

First 27 Last

Share
Profile

Follow
bevter

26,651 Posts.

1330

16/04/25

16:59

Post #: 78717348
Share
Originally posted by gosh ↑

Products for ED and dysmenorrhea have been developed and are currently undergoing stability studies ahead
of submission to the TGA for approval.
above is from page 3 cut and paste....

505(b)2-type formulation development

The 505(b)(2) pathway offers pharmaceutical companies a strategic advantage by reducing the time and financial investment typically required for the conventional full NDA. This approach bypasses the need for numerous nonclinical studies and extensive safety and efficacy tests.

This pathway specifically benefits new drugs similar to already approved drugs but have slight variations in formulation or administration routes. Before the Waxman/Hatch Act, approval for such drugs depended on extensive literature-based arguments provided by the applicant to prove the safety and efficacy of the new product.

Applicants can now reference the safety and efficacy data of the original innovator drug without needing a right of reference. This is possible because the API remains unchanged, implying inherent similarities in safety and efficacy between the new and original products.

While some differences in formulation or administration might require additional clinical studies for 505(b)(2) applicants, these are typically less extensive than what’s required for original innovator drugs. In many cases, a bioequivalence study suffices to demonstrate the similarity between the two drugs, leading to FDA approval. In instances where additional clinical studies are needed, the requirements are generally less stringent.

Again, the pathway also presents an opportunity for market exclusivity ranging from 3 to 7 years.

Unlike the traditional 505(b)(1) pathway, which can take up to 15 years and cost millions or even a billion dollars, the 505(b)(2) pathway offers a faster and less expensive route to market.

Key differences in the product planning phase include:

Leveraging existing data: Look for ways to incorporate data from the public domain and the FDA's previous findings to reduce the size, scope, timeline, and cost of development.

Exclusivity potential: Products approved under 505(b)(2) may qualify for various types of market exclusivity:

Orphan drug exclusivity (7 years)

New chemical entity exclusivity (5 years)

"Other" exclusivity (3 years for a "change" if certain criteria are met)

Pediatric exclusivity (6 months added to existing patents/exclusivity)

Expand

Sorta makes me laugh "the safety and efficacy data" Where was that when they
released an untested vax on the whole population with no ingredients listed
which would alone have turned people off. Double standards when Big Pharma's involved.
EVE Price at posting: 0.1¢ Sentiment: Hold Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

Gold, Brent Crude spike as Israel strikes Iran in worst-case scenario

ASX

ASX Ltd notches upward on sale of company meant to fix CHESS 3 years ago

CUV

Clinuvel shares dip, even as CEO comes back from temp leave

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

RML

Resolution's dual-listing to 'expedite growth' – and sets stage for NASDAQ foray

AVM

'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits

MEG

Iberian expansion: Megado turns to Europe with Spanish copper mines

HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back

Zip's stunning comeback: Is this the start of a $14 revival?

First 27 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 3.5¢		Change 0.000(0.00%)		Mkt cap ! $8.585M

Open	High	Low	Value	Volume
3.5¢	3.6¢	3.5¢	$63.64K	1.793M

Buyers (Bids)

No.	Vol.	Price($)
1	187500	3.4¢

Sellers (Offers)

Price($)	Vol.	No.
3.5¢	92845	1

View Market Depth

No.	Vol.	Price($)
1	187500	0.034
1	143003	0.033
1	271038	0.032
3	265000	0.030
1	200000	0.027

Price($)	Vol.	No.
0.035	92845	1
0.039	15000	1
0.040	446825	2
0.041	12584	1
0.044	25000	1

Last trade - 16.10pm 13/06/2025 (20 minute delay)

EVE (ASX) Chart

Sorta makes me laugh "the safety and efficacy data" Where was...

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

Gold, Brent Crude spike as Israel strikes Iran in worst-case scenario

ASX Ltd notches upward on sale of company meant to fix CHESS 3 years ago

Clinuvel shares dip, even as CEO comes back from temp leave

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Resolution's dual-listing to 'expedite growth' – and sets stage for NASDAQ foray

'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits

Iberian expansion: Megado turns to Europe with Spanish copper mines

HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back

Zip's stunning comeback: Is this the start of a $14 revival?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Sorta makes me laugh "the safety and efficacy data" Where was...

Top Stories

Week 24 Wrap: WW3 looms (again); US econ data tepid & silver surfing

Gold, Brent Crude spike as Israel strikes Iran in worst-case scenario

ASX Ltd notches upward on sale of company meant to fix CHESS 3 years ago

Clinuvel shares dip, even as CEO comes back from temp leave

Listen: HotCopper Wire Podcast 013 - They changed the IPO rules (and that's a good thing)

Resolution's dual-listing to 'expedite growth' – and sets stage for NASDAQ foray

'Sure to be busy': Advance's Yuquivo drilling gets off to top start with first-hole hits

Iberian expansion: Megado turns to Europe with Spanish copper mines

HotCopper Highlights, Week 24: Israel boosts Energy; Meeka eyes production & Mag7 back

Zip's stunning comeback: Is this the start of a $14 revival?

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News